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osting by EAbstract Acute Myeloid Leukemia (AML)-M0 is a cancer of blood-forming cells in the bone mar-
row. KIT gene is a receptor tyrosine kinase class III that is expressed on by early hematopoietic
progenitor cells and plays an important role in hematopoietic stem cell proliferation, differentiation
and survival. Mutations of KIT receptor tyrosine kinase are involved in the constitutive activation
and development of human hematologic malignancies. We have designed this study aiming to iden-
tify and determine the frequency and prevalence of mutations in North Indian patients suffering
from AML-M0. To perceive the KIT gene mutations, we have carried out PCR–SSCP followed
by direct DNA sequencing in 50 AML-M0 cases. We have found eight cases (24.2%) with
t(8;21) having 12 point mutations whereas three cases (17.6%) with inv(16) having four point muta-
tions. The point mutation detected at exon 9 in ﬁve cases is Asp496Val. Eight different point muta-
tions were identiﬁed at exon 11 in seven AML-M0 cases that include Lys550Asn, Tyr568Ser,
Ile571Leu, Tyr578Pro, Trp582Ser and Arg588Met. Point mutations at codons Ile571Leu and
Trp582Ser was found in two independent cases. Three point mutations were found in exon 17
(Leu813Pro, Lys818Arg, Val825Ala) in three AML-M0 cases. The results underline that the KIT
gene appears to be most frequently mutated target in AML-M0 cases. These observations suggest2408122/2408123.
om (S.R. Hussain).
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134 S.R. Hussain et al.that mutations in exon 11 of the KIT gene might be useful molecular genetic markers in AML-M0
and these mutations might be related to progression and clinical pathogenesis.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
KIT, a proto-oncogene is a member of the type III receptor
tyrosine kinase (RTK) family [1] and plays a crucial role in
normal haematopoiesis and acute myeloid leukemia (AML)
[2,3]. The activation sphere of the receptor has resulted in
the constitutive KIT kinase activity and KIT receptors harbor-
ing such mutations when introduced into mammalian cells
downstream signaling pathways lead to factor-independent
growth in vitro and leukemogenesis in vivo [4,5]. The genomic
locus encoding the KIT gene receptor has 21 exons, ranging
100–300 bp [6] among various factors, mutations for cell dif-
ferentiation and proliferation are considered to be effective
factors in the development of AML [7]. Leukemia is classiﬁed
based on the presence of speciﬁc cytogenetic abnormalities as
well as the French–American–British (FAB) classiﬁcation of
the leukemic cells [8]. AML is a heterogeneous disease in
which hematopoietic progenitor cells acquire genetic lesions
that lead to a block in differentiation, increased self-renewal,
and unregulated proliferation [9]. In 1991 the FAB group pub-
lished a proposal to designate minimally differentiated acute
myeloid leukemia as AML-M0. By deﬁnition, the diagnosis
of AML-M0 requires less than 3% MPO/ and/or SBB/blasts,
expression of myeloid-associated markers, and lack of B/T-
lineage-associated antigens [10]. Abnormalities in genes that
are involved in signal transduction pathways are common in
AML. Mutations in the KIT and FLT3 RTK have been de-
scribed frequently in AML [11]. It is evident from several stud-
ies that there is a high expression of KIT in AML cases (60–
80%) [12,13]. KIT point mutations have been reported in
33.35–45% of AML cases together with inv(16) and 12.8–
46.8% of AML M2 along with t(8;21) [14–16]. Intriguingly,
KIT mutations have been preferentially associated with
AML exhibiting either an inv(16) or a t(8;21) karyotype, i.e.
the core binding factor leukemias [14]. Point mutations of
KIT have been found in approximately 5% of AML samples
[17]. KIT mutation provides the myeloid blasts with the extra
hit by conferring proliferation and anti-apoptotic activity, as
the chimeric transcription factor impairs normal differentia-
tion but has a limited effect on cellular proliferation [18].
Although, many studies screened KIT mutations but only in
a proportion of KIT coding sequence and others were limited
by small case number. Additional chromosomal abnormalities
are frequently associated with t(8;21) and trisomy 4 in partic-
ular has freshly been suggested to constitute a individual sub-
type of t(8;21) AML [19]. Findings of studies investigating the
molecular consequences of trisomy 4 focus on the dosage ef-
fect resulting from the duplication of a mutated KIT allele
[20]. Until now, no study has reported the frequency and prev-
alence of mutations in exon 9, 11 and 17 of KIT gene in AML-
M0 cases in India. In this study we have screened the mutation
status of KIT gene in AML-M0 and further explored whether
the KIT gene mutations frequently occurs in AML-M0. Due
to insufﬁcient studies of the mutations in North India, the
diagnosis and frequency of these mutations in AML-M0 pa-
tients are an important concern.2. Subjects and methods
2.1. Specimen collection
The study group included 50 cases of AML-M0. Ethical ap-
proval was obtained from the institutional ethical committee
of Era’s Lucknow Medical College and Hospital, Lucknow,
Uttar Pradesh, India. The bone marrow samples were stained
by Leishman stain method and cases were classiﬁed, according
to the French American British (FAB) criteria [10]. The study
was carried out during June 2006 to May 2011.
2.2. Molecular studies
Specimens collected were 50 bone marrow slides diagnosed as
leukemia from the Department of Pathology at Era’s Lucknow
Medical College and Hospital and other hospitals and pathol-
ogy centers in Lucknow. Extraction of genomic DNA was
done by using a commercially available DNA extraction kit
(Medox, India) and the DNA was stored at 20 C.
2.2.1. Polymerase chain reaction
Polymerase chain reaction (PCR) was performed with 20 ll
PCR reaction mixture containing 250 ng of template DNA,
20 pmol of each primer, 10 mmol/L of each mix dNTPs, 1·
reaction buffer and 1 unit of Taq polymerase enzyme (Fermen-
tas, Germany) in an MJ Mini Thermocycler (Bio-Rad, UK).
The cycling conditions included preliminary denaturation at
95 C for 5 min, 40 cycles of denaturation at 95 C for 30 s, fol-
lowed by annealing at 55 C for 30 s, and extension at 72 C
for 30 s. A ﬁnal extension was given at 72 C for 10 min using
the primers for Exon 9 Forward 50-GGC TTT TGT TTT CTT
CCC TTT -30 and Reverse 50- GAA GTC TTG CCC ACA
TCG TT -30 [Designed by JustBio.com software], Exon 11 For-
ward 50-ATT ATT AAA AGG TGA TCT ATT TTT C-30 and
Reverse 50-ACT GTT ATG TGT ACC CAA AAA G-30, Exon
17 Forward 50-TTC ACT CTT TAC AAG TTA AAA TG-30
and Reverse 50-GGA CTG TCA AGC AGA GAA TG-30 [21].
2.2.2. Mutational screening of KIT exons
Single-strand conformational polymorphism (SSCP) analysis
was performed according to Orita et al. [22] with little modiﬁca-
tions. Samples were denatured at 95 C for 6 min with denatur-
ing dye and immediately transferred to ice. Fifteen microliter of
ampliﬁed PCR product was loaded along with 15 ll of denatur-
ing dye on 10%polyacrylamide gel. Gel was run in pre-cooled 1·
TBE buffer (Tris–Borate EDTA). The gel tank was placed in a
cold room at 4 C and run for 12 h at 150 V. DNA on the gel
was stained after electrophoresis with silver stain. Electrophore-
sis mobility shift in single-stranded or double stranded DNA
product from patients was detected by comparison with DNA
product from normal controls run in adjacent lanes (Fig. 1).
2.2.3. KIT mutational analysis
Amplicons were sequenced using an automated sequencer,
ABI 3730XL DNA Analyzer (Applied Biosystems, Foster city,
Figure 1 SSCP–PAGE showing electrophoresis mobility shift on native page. Control in Lane 1 and cases in 2, 3, 4 and 5th lane (no shift
in case 02; shift in case 12, 20 and no result in case 27).
A study of KIT activating mutations in acute myeloid leukemia M0 subtype in north India 135California, USA). Mutations were reconﬁrmed by sequencing
amplicons in both directions and in independent second sam-
ples. Sequence was analyzed using the FinchTV, BioEdit and
BLAST (National Center for Biotechnology Information)
software.
3. Results
The study comprised of bone marrow slides from 27 males and
23 females with age ranging from 5 years to 60 years. The
mean age of onset of AML was 30.3 years and SD± 1.00
(mean age of male cases was 23.0 years, SD ± 3.25 and mean
age of female cases was 40 years, SD ± 5.30) years. The med-
ian WBC count in the cases was 40,000 cells/ll/cumm (ranging
from 15,000 to 74,000 cells/ll/cumm) and the median count of
blast cells was 70% (ranging from >40% to >80%). Out of
50 AML cases, 33 cases carried t(8;21) and 17 cases had
inv(16). (Table 1).
3.1. Mutational analysis of exon 9
Out of 50 AML cases, 21 samples displayed a shift in position
in native SSCP–PAGE. These were directly sequenced by an
automated sequencer. Five point mutations were detected in
ﬁve AML-M0 cases (Table 2 and Table 3).
3.2. Mutational analysis of exon 11
Out of 50 AML cases, 33 samples displayed a shift in position
in native SSCP–PAGE. These were directly sequenced by an
automated sequencer. Eight point mutations were detected in
seven AML-M0 cases (Table 2 and Table 3).
3.3. Mutational analysis of exon 17
Out of 50 AML cases, 27 samples displayed a shift in position
in native SSCP–PAGE. These were directly sequenced by an
automated sequencer. Three point mutations were detected
in three AML-M0 cases (Table 2 and Table 3).4. Discussion
This study is the ﬁrst to report mutations in the KIT gene in
AML-M0 cases in north India. Previous molecular studieshave revealed several mutations in different types of tumors
in different ethnic groups. Mutations in exons 9, 13 and 17
of the KIT gene are less frequently detected than in exon 11
in different types of neoplasia [23–25]. In gastrointestinal stro-
mal tumors, 65–92% of tumors are reported to harbor KIT-
activating mutations, the majority of which are localized in
the juxtamembrane region involving exon 11 [23]. The majority
of exon 11 mutations is clustered within the classic hotspot re-
gion of the 50 end involving codons 550–560; however, a sec-
ond hotspot at the 30 end involving codons 576–590 has been
described by Antonescu et al. [26]. These include frame dele-
tions of one to several codons (typically involving codons
557–560); point mutations and internal tandem duplications
(typically involving the 30 end).
In our study, when the samples were analyzed on the basis of
cytogenetics, there were two major sets: Set I comprised of 33
cases having t(8;21) and Set II comprised of 17 cases having
inv(16). When these cases were further analyzed for kit muta-
tions at exon 9, 11 and 17, we found that eight cases (24.2%)
with t(8;21) showed 12 point mutations whereas three cases
(17.6%) with inv(16) showed four point mutations. The point
mutation detected at exon 9 in ﬁve cases is Asp496Val which
has already been reported [25] (Table 2 and Table 3). Eight dif-
ferent point mutations were identiﬁed at exon 11. The point
mutations Lys550Asn and Ile571Leu detected in our study have
been previously reported [24,27] and the mutation Ile571Leu is
detected in two independent cases. The mutations at codon 582
reported by Tae et al. [28] are Trp582Tyr and Trp582His,
whereas by Ying-Yong et al. [29] are Trp582Try and
Trp582Gln, but we have detected different substitution at the
same codon in which tryptophan is replaced by serine
(Trp582Ser) in two independent cases. Mutations at codons
Tyr568Asp, Tyr578Phe, and Arg588Phe, Arg588Tyr, Arg588
Lys have been reported by Tae et al. [28], Masahiko et al.
[30], Ying-Yong et al. [29]. At Exon 17 we detected three point
mutations at codons Leu813Pro, Lys818Arg and Val825Ala
[25,31,32]. Noteworthy to quote here, that we have identiﬁed
point mutations at exon 9, 11 and 17 in eleven cases. The c-kit
gene exon 9, 11 and 17 mutations detected during our study, lo-
cated between codons 450–500 in exon 9, 550–591 in exon 11
and 788–828 in exon 17, endorse previous studies reporting
mutations in different populations with neoplasia which has
been summarized in Table 2 and Table 3. The majority of muta-
tions detected in our study was found in cases with high count of
WBC and Blast cells as shown in Table 1 and might be
Table 2 Amino acid sequences of KIT gene point mutations at exon 9 (codon 450–500), 11 (codon 550–591) and 17 (codon 788–828).
Table 1 Clinical and genetic features with cytogenetic ﬁndings of 50 AML-M0 cases.
Total t(8;21) inv(16) Total
KIT(+) mutation KIT() mutation Total KIT(+) mutation KIT() mutation
n % n % n n % n % n
8 24.2 25 75.7 33 3 17.6 14 82.3 17
Age (years)
660 5 62.5 3 37.5 8 1 12.5 7 87.5 8
>60 3 12 22 88 25 2 22.2 7 77.7 9
Sex
Male 4 23.5 13 76.4 17 1 10 9 90 10
Female 4 25 12 75 16 2 28.5 5 71.4 7
WBC
640· 109/L 6 42.8 8 57.1 14 3 33.3 6 66.6 9
>40· 109/L 2 10.5 17 89.4 19 0 0 8 100 8
Blast cells
680 5 41.6 7 58.3 12 1 7.69 12 92.3 13
>80 3 14.2 18 85.7 21 2 50 2 50 4
136 S.R. Hussain et al.associated with disease development and prognosis. Basically,
these mutations are huddled in the same region as other known
KIT 16 mutations and most probably code for a constitutively
activated protein. It is worth mentioning here that our study is
the ﬁrst to report the presence of KIT gene mutations in AML-
M0 cases in north India. These ﬁndings point toward an impor-
tant mutational part of KIT exon 8, 9 and 17 mutations in the
pathogenesis of AML-M0 and provide the source for the KIT
gene that might represent useful molecular genetic marker in
AML-M0.5. Conclusion
AML-M0 is heterogeneous with respect to morphology, cyto-
chemistry, immunophenotyping, cytogenetics, and molecular
genetics. At present, we still lack a speciﬁc marker or a set of
biological and/or clinical features to single out this FAB sub-
type as a distinct disease entity. This study is ﬁrst to report
the presence of KIT gene mutations in AML-M0 cases in
north India. These mutations in exon 11 may be involved in
KIT over-expression in AML-M0 cases as these mutations
Table 3 Summary of KIT gene point mutations at exon 9, 11 and 17 in AML-M0 cases.
Case no. Exons Substitution Mutations (our study) Reported mutations
3 Exon 9
Exon 17
GATﬁGTT
CTAﬁCCA
Asp496Val
Leu813Pro
Asp496Val
Leu813Pro
[25]
[25]
9 Exon 11 TATﬁTCT
TGG ﬁTCA
Tyr568Ser
Trp582Ser
Tyr568Asp
Trp582Tyr, Trp582His, Trp582Gln
[30]
[21,28]
10 Exon 11 AGGﬁATG Arg588Met Arg588Phe, Arg588Tyr, Arg588Lys [28,29]
11 Exon 11 ATAﬁCTA Ile571Leu Ile571Leu [27]
12 Exon 9
Exon 11
GATﬁGTT
ATAﬁCTA
Asp496Val
Ile571Leu
Asp496Val
Ile571Leu
[25]
[27]
13 Exon 11 AAAﬁAAC Lys550Asn Lys550Asn [24]
20 Exon 9
Exon 11
GATﬁGTT
TATﬁCCT
Asp496Val
Tyr578Pro
Asp496Val
Tyr578Phe
[25]
[28]
23 Exon 9
Exon 11
GATﬁGTT
TGG ﬁTCA
Asp496Val
Trp582Ser
Asp496Val
Trp582Tyr, Trp582His, Trp582Gln
[25]
[21,28]
27 Exon 9 GATﬁGTT Asp496Val Asp496Val [25]
39 Exon 17 AAGﬁAGG Lys818Arg Lys818Arg [31]
46 Exon 17 GTTﬁGCT Val825Ala Val825Ala [32]
A study of KIT activating mutations in acute myeloid leukemia M0 subtype in north India 137are located in Juxtamembrane domain. These observations
suggest that mutations in exon 11 of the KIT gene might be
useful molecular genetic markers in AML-M0 and these muta-
tions might be related to progression and clinical pathogenesis.Acknowledgments
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